Decoding genome of cancer - new & exciting other breaking news

[Guest guest]

WASHINGTON - Scientists for the first time have decoded the entire genome of a

cancer patient, identifying a series of genes never before linked to the type of

white blood cell cancer that ultimately killed the woman. The study, published

on Wednesday in the journal Nature, represents a new approach to grasp the

genetic underpinning of cancer and pave the way for better treatments,

researchers at Washington University School of Medicine in St. Louis said. A

deeper genetic understanding of cancer -- now possible with speedier, cheaper

DNA sequencing technology -- can serve as the foundation for developing more

effective ways to diagnose and treat cancer, the researchers said.

http://www.comcast.net/articles/news-science/20081105/SCIENCE-US-CANCER-GENOME/

_________________________________________

In an effort to recruit even more volunteer stem cell donors from varied ethnic

communities, Canada's OneMatch Stem Cell and Marrow Network has begun to offer

services in languages other than English and French. Today, more than 600

patients across Canada require a life-saving stem cell transplant for cancers

such as leukemia, lymphoma and myeloma, as well as for other immune and genetic

disorders. http://www.medicalnewstoday.com/rss/lymphoma-leukemia.xml

__________________________________________________

Pre-Clinical Data on RGB-286638 dated October, 2998. The data presented today

support the potential utility of RGB-286638 against some hematological

malignancies, " said e , M.D., Senior Vice President, Drug

Development and Chief Medical Officer of GPC Biotech. " We are particularly

excited to see the strong effect that RGB-286638 has against Gleevec- or

Sprycel-resistant tumor cells. These data are supportive of our clinical plans

for RGB-286638: We expect to initiate a Phase 1 trial in solid tumors in the

near future, followed by a study in hematological tumors, including CML, during

2009. This compound has been shown in cancer cells to lead to the inhibition

of cell cycle progression, the process that controls cell division and ensures

the accurate duplication of genetic material, by targeting all relevant

cyclin-dependent kinases, which are proteins involved in regulating the cell

cycle. http://www.medicalnewstoday.com/articles/126979.php

This small molecule has potent activity against chronic myeloid leukemia (CML)

in in vivo models that are resistant to imatinib (Gleevec®) and to dasatinib

(Sprycel®), the current standards of care for treating this form of cancer.

Additionally, RGB-286638 has been shown in vitro to be active against a number

of families of protein kinases that are important for the proliferation of

cancer cells. RGB-286638 is expected to enter Phase 1 clinical testing this

year.

http://www.gpc-biotech.com/en/news_media/press_releases/2008/10-27-08.html

____________________________________

Good reading FYI,

Lottie

[Guest guest]

How amazing is some of these specialists and scientists.

To decode genetic materials etc.

You just have to be in awe of these people.

If I had AML you would have to go WOW !!! even if it is 20 years time to get

treatments.

Do you mind Lottie if I post this info on our Aussie bulletin?

--------------------------------------------------------------------------------

I liked the info that stated around 13,000 people a year get AML

Our little CML clubbies stay pretty stable with the 280 - 350 in Australia and

4000 to 4500 thousand

in America.

I now state how lucky am I to get CML and not one of the other conditions.

--------------------------------------------------------------------------------

Keep well ALL meaning everyone (not another blood condition)

Cheers

Sue